Lancet for Prana
Wednesday, 30 July, 2008
A recent clinical trial has shown that PBT2 improves executive function and lowers spinal Abeta levels in Alzheimer's patients
The data from clinical trials of Prana Biotechnology's [ASX: PBT] Phase IIa clinical trials of PBT2 in Alzheimer's patients has been published in the Lancet Neurology journal.
The data shows that PBT2 was able to improve executive function in patients with early stage Alzheimer's disease. PBT2 works also reduces Abeta levels in the spinal fluid of patients.
The 78 trial participants experienced no serious adverse effects. The data shows that Abeta levels were reduced by an average of 13 per cent.
The data from Prana's earlier preclinical trials was recently published in Neuron.
Scientists uncover how cancer cells hide from immune system
By targeting the RNA helicase known as DDX6, scientists could enable the immune system to...
Vanillin flavouring in vapes may disrupt embryo development
Vanillin — a common flavouring chemical in e-cigarettes — may disrupt the normal...
Heart valve tissues created from stem cells
The breakthrough should help advance our understanding into how human heart valves develop,...
